BACKGROUND: Wilms tumor is one of the most common solid tumors in children. A transforming growth factor-alpha (TGF-alpha)/epidermal growth factor receptor (EGF-R) autocrine loop plays an important role in tumor growth. Abnormal expression of TGF-alpha, EGF-R and c-erb B-2 has been demonstrated in several human malignancies. METHODS: The immunohistochemical expression of TGF-alpha, EGF-R, and c-erb B-2 was studied in paraffin material of 62 clinical Wilms tumors. Patients had a mean follow-up of 5.7 years. RESULTS: Generally, TGF-alpha, EGF-R, and c-erb B-2 were expressed in tissue of the normal kidney and at variable levels in the three cell types of Wilms tumor, i.e., blastemal, epithelial, and stromal cells. Immunoreactive blastema cells were found in 48%, 44%, and 34% of tumors for TGF-alpha, EGF-R, and c-erb B-2, respectively. It was found that TGF-alpha, EGF-R, and c-erb B-2 blastemal and epithelial expression gradually increased from T1 to T3. The blastemal expression of TGF-alpha was statistically significantly correlated with clinicopathologic stages. Both univariate and multivariate analysis showed that blastemal TGF-alpha expression was indicative for clinical progression, but neither blastemal TGF-alpha, nor EGF-R or c-erb B-2 expression correlated with patients survival. Epithelial staining was of no prognostic value. The simultaneous expression of TGF-alpha/EGF-R was indicative for clinical progression at univariate level. CONCLUSIONS: Increased expression of TGF-alpha in the blastemal part of Wilms tumor correlated with tumor classification and clinical progression. These findings suggest that significant expression of TGF-alpha and EGF-R may play a role in promoting transformation and/or proliferation of Wilms tumor, perhaps by an autocrine mechanism. Therefore, their expression may be of value in identifying patients at high risk of tumor recurrence. Copyright 2001 American Cancer Society.
BACKGROUND:Wilms tumor is one of the most common solid tumors in children. A transforming growth factor-alpha (TGF-alpha)/epidermal growth factor receptor (EGF-R) autocrine loop plays an important role in tumor growth. Abnormal expression of TGF-alpha, EGF-R and c-erb B-2 has been demonstrated in several humanmalignancies. METHODS: The immunohistochemical expression of TGF-alpha, EGF-R, and c-erb B-2 was studied in paraffin material of 62 clinical Wilms tumors. Patients had a mean follow-up of 5.7 years. RESULTS: Generally, TGF-alpha, EGF-R, and c-erb B-2 were expressed in tissue of the normal kidney and at variable levels in the three cell types of Wilms tumor, i.e., blastemal, epithelial, and stromal cells. Immunoreactive blastema cells were found in 48%, 44%, and 34% of tumors for TGF-alpha, EGF-R, and c-erb B-2, respectively. It was found that TGF-alpha, EGF-R, and c-erb B-2 blastemal and epithelial expression gradually increased from T1 to T3. The blastemal expression of TGF-alpha was statistically significantly correlated with clinicopathologic stages. Both univariate and multivariate analysis showed that blastemal TGF-alpha expression was indicative for clinical progression, but neither blastemal TGF-alpha, nor EGF-R or c-erb B-2 expression correlated with patients survival. Epithelial staining was of no prognostic value. The simultaneous expression of TGF-alpha/EGF-R was indicative for clinical progression at univariate level. CONCLUSIONS: Increased expression of TGF-alpha in the blastemal part of Wilms tumor correlated with tumor classification and clinical progression. These findings suggest that significant expression of TGF-alpha and EGF-R may play a role in promoting transformation and/or proliferation of Wilms tumor, perhaps by an autocrine mechanism. Therefore, their expression may be of value in identifying patients at high risk of tumor recurrence. Copyright 2001 American Cancer Society.
Authors: Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent Journal: Am J Pathol Date: 2011-10-08 Impact factor: 4.307
Authors: M Salem; Y Kinoshita; T Tajiri; R Souzaki; K Tatsuta; M Higashi; T Izaki; K Kohashi; M Tsuneyoshi; T Taguchi Journal: Pediatr Surg Int Date: 2006-11 Impact factor: 1.827
Authors: Bhalchandra A Diwan; Olga Timofeeva; Jerry M Rice; Yili Yang; Nirmala Sharma; Mark E Fortini; Honghe Wang; Alan O Perantoni Journal: Differentiation Date: 2009-01-29 Impact factor: 3.880
Authors: Serena S Freeman; Steven W Allen; Ramapriya Ganti; Jianrong Wu; Jing Ma; Xiaoping Su; Geoff Neale; Jeffrey S Dome; Najat C Daw; Joseph D Khoury Journal: Cancer Date: 2008-09-15 Impact factor: 6.860
Authors: Sylvia C Wetli; Ivo Leuschner; Dieter Harms; Alex Rufle; Anja Foerster; Michel Bihl; Norbert Graf; Roikos Furtwaengler; Michael Paulussen; Jakob Briner; Charalampos Aslanidis; Gerd Schmitz; Luigi Tornillo; Michael J Mihatsch; Inti Zlobec; Elisabeth Bruder Journal: Virchows Arch Date: 2008-05-14 Impact factor: 4.064
Authors: Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh Journal: J Urol Date: 2016-05-31 Impact factor: 7.450
Authors: Tanya M Trippett; Cynthia Herzog; James A Whitlock; Johannes Wolff; John Kuttesch; Rochelle Bagatell; Stephen P Hunger; Jessica Boklan; Amy A Smith; Robert J Arceci; Howard M Katzenstein; Christopher Harbison; Xiaofei Zhou; Haolan Lu; Christiane Langer; Martin Weber; Lia Gore Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 50.717